Nuclear Accumulation of Histone Deacetylase 4 (HDAC4) Coincides with the Loss of Androgen Sensitivity in Hormone Refractory Cancer of the Prostate

K. Halkidou, S. Cook, H. Y. Leung, D. E. Neal, C. N. Robson, William G Nelson

Research output: Contribution to journalArticle

Abstract

Objectives: To examine the effect of androgen treatment upon histone deacetylase 4 (HDAC4) localisation and, thus, enzymatic function in androgen sensitive prostate cancer (CaP) models. To study HDAC4 expression in benign prostatic hyperplasia, primary and hormone refractory (HR) CaP and to investigate the involvement of histone deacetylase activity in the development of the androgen insensitive phenotype. Methods: Immunohistochemical staining of prostate sections of both benign tissue and primary and hormone relapsed prostate cancer, as well as of the CWR22 mouse xenograft model, and indirect quantitative immunofluorescence staining of endogenous HDAC4 in LNCaP cells. Results: HDAC4 is recruited to the nuclei of HR cancer cells, where it may exert an inhibitory effect on differentiation and contribute to the development of the aggressive phenotype of late stage CaP. The above may result from the loss of androgen responsiveness characterising HR CaP, since HDAC4 nuclear localisation is regulated by androgens in androgen responsive systems (i.e. LNCaP, CWR22) reflecting earlier phase disease. Conclusions: HDAC4 may contribute to the development of HR CaP and, therefore, constitute a potential therapeutic target, particularly in the most lethal phase of androgen independence.

Original languageEnglish (US)
Pages (from-to)382-389
Number of pages8
JournalEuropean Urology
Volume45
Issue number3
DOIs
StatePublished - Mar 2004
Externally publishedYes

Fingerprint

Histone Deacetylases
Androgens
Prostatic Neoplasms
Hormones
Staining and Labeling
Phenotype
Prostatic Hyperplasia
Indirect Fluorescent Antibody Technique
Heterografts
Prostate
Therapeutics
Neoplasms

Keywords

  • Histone deacetylase 4
  • Hormone refractory
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Nuclear Accumulation of Histone Deacetylase 4 (HDAC4) Coincides with the Loss of Androgen Sensitivity in Hormone Refractory Cancer of the Prostate. / Halkidou, K.; Cook, S.; Leung, H. Y.; Neal, D. E.; Robson, C. N.; Nelson, William G.

In: European Urology, Vol. 45, No. 3, 03.2004, p. 382-389.

Research output: Contribution to journalArticle

@article{986934998f25444785fa462647979964,
title = "Nuclear Accumulation of Histone Deacetylase 4 (HDAC4) Coincides with the Loss of Androgen Sensitivity in Hormone Refractory Cancer of the Prostate",
abstract = "Objectives: To examine the effect of androgen treatment upon histone deacetylase 4 (HDAC4) localisation and, thus, enzymatic function in androgen sensitive prostate cancer (CaP) models. To study HDAC4 expression in benign prostatic hyperplasia, primary and hormone refractory (HR) CaP and to investigate the involvement of histone deacetylase activity in the development of the androgen insensitive phenotype. Methods: Immunohistochemical staining of prostate sections of both benign tissue and primary and hormone relapsed prostate cancer, as well as of the CWR22 mouse xenograft model, and indirect quantitative immunofluorescence staining of endogenous HDAC4 in LNCaP cells. Results: HDAC4 is recruited to the nuclei of HR cancer cells, where it may exert an inhibitory effect on differentiation and contribute to the development of the aggressive phenotype of late stage CaP. The above may result from the loss of androgen responsiveness characterising HR CaP, since HDAC4 nuclear localisation is regulated by androgens in androgen responsive systems (i.e. LNCaP, CWR22) reflecting earlier phase disease. Conclusions: HDAC4 may contribute to the development of HR CaP and, therefore, constitute a potential therapeutic target, particularly in the most lethal phase of androgen independence.",
keywords = "Histone deacetylase 4, Hormone refractory, Prostate cancer",
author = "K. Halkidou and S. Cook and Leung, {H. Y.} and Neal, {D. E.} and Robson, {C. N.} and Nelson, {William G}",
year = "2004",
month = "3",
doi = "10.1016/j.eururo.2003.10.005",
language = "English (US)",
volume = "45",
pages = "382--389",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Nuclear Accumulation of Histone Deacetylase 4 (HDAC4) Coincides with the Loss of Androgen Sensitivity in Hormone Refractory Cancer of the Prostate

AU - Halkidou, K.

AU - Cook, S.

AU - Leung, H. Y.

AU - Neal, D. E.

AU - Robson, C. N.

AU - Nelson, William G

PY - 2004/3

Y1 - 2004/3

N2 - Objectives: To examine the effect of androgen treatment upon histone deacetylase 4 (HDAC4) localisation and, thus, enzymatic function in androgen sensitive prostate cancer (CaP) models. To study HDAC4 expression in benign prostatic hyperplasia, primary and hormone refractory (HR) CaP and to investigate the involvement of histone deacetylase activity in the development of the androgen insensitive phenotype. Methods: Immunohistochemical staining of prostate sections of both benign tissue and primary and hormone relapsed prostate cancer, as well as of the CWR22 mouse xenograft model, and indirect quantitative immunofluorescence staining of endogenous HDAC4 in LNCaP cells. Results: HDAC4 is recruited to the nuclei of HR cancer cells, where it may exert an inhibitory effect on differentiation and contribute to the development of the aggressive phenotype of late stage CaP. The above may result from the loss of androgen responsiveness characterising HR CaP, since HDAC4 nuclear localisation is regulated by androgens in androgen responsive systems (i.e. LNCaP, CWR22) reflecting earlier phase disease. Conclusions: HDAC4 may contribute to the development of HR CaP and, therefore, constitute a potential therapeutic target, particularly in the most lethal phase of androgen independence.

AB - Objectives: To examine the effect of androgen treatment upon histone deacetylase 4 (HDAC4) localisation and, thus, enzymatic function in androgen sensitive prostate cancer (CaP) models. To study HDAC4 expression in benign prostatic hyperplasia, primary and hormone refractory (HR) CaP and to investigate the involvement of histone deacetylase activity in the development of the androgen insensitive phenotype. Methods: Immunohistochemical staining of prostate sections of both benign tissue and primary and hormone relapsed prostate cancer, as well as of the CWR22 mouse xenograft model, and indirect quantitative immunofluorescence staining of endogenous HDAC4 in LNCaP cells. Results: HDAC4 is recruited to the nuclei of HR cancer cells, where it may exert an inhibitory effect on differentiation and contribute to the development of the aggressive phenotype of late stage CaP. The above may result from the loss of androgen responsiveness characterising HR CaP, since HDAC4 nuclear localisation is regulated by androgens in androgen responsive systems (i.e. LNCaP, CWR22) reflecting earlier phase disease. Conclusions: HDAC4 may contribute to the development of HR CaP and, therefore, constitute a potential therapeutic target, particularly in the most lethal phase of androgen independence.

KW - Histone deacetylase 4

KW - Hormone refractory

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=1242315436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242315436&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2003.10.005

DO - 10.1016/j.eururo.2003.10.005

M3 - Article

C2 - 15036687

AN - SCOPUS:1242315436

VL - 45

SP - 382

EP - 389

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 3

ER -